By H. J. Bensted, W. Bulloch, L. Dudgeon, A. G. Gardner, E. D. W. Greig, D. Harvey, W. F. Harvey, T. J. Mackie, R. A. O'Brien, H. M. Perry, H. Scutze, P. Bruce White, W. J. Wilson. London, 1929. His Majesty's Stationery Office. Pp. 1–482
by A. Trevor Willis, M.D., B.S. (Melb.), Ph.D. (Leeds), M.C.Path., M.C.P.A., Reader in Microbiology, Monash University, formerly Lecturer in Bacteriology, University of Leeds. xiv + 234 pages, illustrated, second edition. Butterworth Inc., Washington. 1965. $8.50
A double-blind placebo-controlled trial of erythromycin ethylsuccinate was conducted in 65 infants and young children hospitalized with acute nonspecific gastroenteritis. Etiologic agents included rotaviruses (29%), Campylobacter jejuni (17%), “classical” enteropathogenic Escherichia coli (12%), enterotoxigenic E. coli (11%), Salmonella (9%), Shigella (2%), and Giardia lamblia (2%). No pathogens were obtained from 25 (38%) children. Treatment with erythromycin had no effect on the course of the illness in terms of the time required for hydration, stool frequency and temperature to return to normal, or for vomiting to be abolished. Children treated with erythromycin, however, experienced a marginally, but significantly (P < 0.05), shorter period of abnormal stool consistency compared with control subjects. This effect was most pronounced in children from whom no enteropathogens were isolated.
Present address: Department of Microbiology, University of Melbourne, Parkville, Victoria 3052, Australia. Send reprint requests to this address.